This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 4441299 results found since Jan 2013.

192 Tacrolimus-induced chronic inflammatory demyelinating polyradiculoneuropa- thy (CIDP): a case series
Conclusion Various case reports have demonstrated a possible association between tacrolimus and CIDP, but this is the largest case series to date. IVIg responsiveness alone is generally poor, but resolution is possible when switching to alternative agents.
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: Evans, M., Dahdaleh, S., Karunaratne, K., Pritchard, J., Rinaldi, S., Viegas, S. Tags: Poster presentations Source Type: research

Objectivity, practicality, and significance of practice guidelines for the practicing neurologists: What we learnt from consensus criteria in CIDP, Myasthenia Gravis and Inflammatory Myopathies
Ther Adv Neurol Disord. 2023 Sep 4;16:17562864231194821. doi: 10.1177/17562864231194821. eCollection 2023.ABSTRACTThe value of practice guidelines in the three most common autoimmune neuromuscular disorders, namely Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Myasthenia Gravis (MG) and Autoimmune Inflammatory Myopathies (AIM), has been extensively debated regarding their usefulness in clinical practice, objectivity and universal value considering that guidelines are also established regionally in certain countries. This commentary highlights common concerns on how guidelines are presently generated, pointing o...
Source: Adv Data - September 7, 2023 Category: Epidemiology Authors: Marinos C Dalakas Source Type: research

Recovery of the T-cell repertoire in CIDP by IV immunoglobulins
Conclusions: Our data demonstrate that cytotoxic CD8+ T cells exhibit a much broader activation than CD4+ T cells, indicating a potentially crucial role of CD8+ T cells in the immunopathogenesis of CIDP. The profound oligoclonal response in T-cell activation suggests that multiple peptides may induce and propagate this autoimmune-driven disease. The observed reduction of highly activated T cells may contribute to the therapeutic effects of IVIg.
Source: Neurology - January 14, 2013 Category: Neurology Authors: Mausberg, A. K., Dorok, M., Stettner, M., Muller, M., Hartung, H. P., Dehmel, T., Warnke, C., Meyer zu Horste, G., Kieseier, B. C. Tags: Autoimmune diseases, Chronic inflammatory demyelinating polyneuropathy ARTICLE Source Type: research

Patient demographics and health plan paid costs in CIDP
We examined demographics, prevalence of comorbidities, prescribed drugs, place of service, and mean annual health plan paid costs per patient. Results: From 6.5 million covered lives, 73 (56% men; mean age 47) met study entry criteria. The most prescribed therapies were intravenous immunoglobulin (IVIg) (26% of patients), gabapentin (26%), and prednisone (16%). The annual health plan paid cost was $56,953. Pharmacy cost was the major cost driver (57% of the total), and IVIg totaled 90% of the pharmacy costs. Discussion: Healthcare costs for CIDP patients are substantial, with a large burden in pharmacy utilization. Studies...
Source: Muscle and Nerve - November 6, 2013 Category: Internal Medicine Authors: Jeffrey T. Guptill, Mark B. Bromberg, Li Zhu, Bal K. Sharma, Amy R. Thompson, Andrew Krueger, Donald B. Sanders Tags: Research Article Source Type: research

Subacute Onset of Severe Cidp Weakness Associated With Tumor-Like Nerve Root Involvement: A Case Report (P6.092)
CONCLUSIONS: Rapid onset with fulminant progression of limb muscle weakness without respiratory compromise and associated tumor-like enlargement of cervical and lumbosacral nerve roots is unusual presentation of CIDP. Other inflammatory, infectious and neoplastic processes need to be eliminated. Continuous immune and supportive therapies are required to secure the best functional outcome.Disclosure: Dr. Stoll has nothing to disclose. Dr. Rakocevic has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Stoll, S., Rakocevic, G. Tags: Neuropathy: Imaging and Biomarkers Source Type: research

Fingolimod (FTY720) Oral For The Treatment Of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Study Design Of The Phase 3 FORCIDP Trial (P6.103)
ConclusionsThis study will provide evidence for whether fingolimod can be a treatment option for patients with CIDP.This study is supported by Novartis Pharma AG, Basel, Switzerland.Disclosure: Dr. Hartung has received personal compensation for activities with Bayer Pharmaceuticals Corp., CSL Behring, Biogen Idec, Genzyme Corp., Grifols, Merck Serono, Novartis, Roche Diagnostics Corp., Teva Neuroscience, and Sanofi-Aventis Pharmaceuticals Inc. as a consultant and speaker. Dr. Sobue has received personal compensation for activities with Novartis as a committee member, and CSL Behring as a consultant. Dr. Dalakas has receive...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Hartung, H., Sobue, G., Dalakas, M., Latov, N., Leger, J.-M., Merkies, I., Nobile-Orazio, E., Agoropoulou, K., Haring, D., Zhang-Auberson, L., Von Rosenstiel, P., Hughes, R. Tags: Neuromuscular Disease Source Type: research

Multicentre, Randomised, Open-Label Trial To Compare Efficacy And Tolerance Of Prednisone And IVIG In Patients With CIDP On A One Year Follow Up (P7.092)
CONCLUSIONS: IVIg and prednisone are effective and safe in 6 month treatment of CIDP. We did not show difference between the treatments but IVIg seem to be faster and more powerful to improve patients when prednisone should have a more lasting effect.STUDY SUPPORTED BY: LFB BIOTECHNOLOGIESDisclosure: Dr. Camdessanche has received research support from LFB Biotechnologies. Dr. Ferraud has nothing to disclose. Dr. Lagrange has nothing to disclose. Dr. Viala has nothing to disclose. Dr. Chan has nothing to disclose. Dr. Guy Renouil has nothing to disclose. Dr. Louis Leonard has nothing to disclose. Dr. Echaniz-Laguna has rece...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Camdessanche, J.-P., Ferraud, K., Lagrange, E., Viala, K., Chan, V., Guy Renouil, N., Louis Leonard, S., Echaniz-Laguna, A., Besson, G., Bouhour, F., Delmont, E., Fromont, A., Gallard, J., Magot, A., Nicolas, G., Uzenot, D., Karine, B.-L., Stojkovic, T., Tags: Neuromuscular Disease: Therapy Source Type: research

An assessment tool for measuring efficacy of ivig in cidp
Conclusion Our assessment tool captures relevant aspects of disease impact in pwCIDP and may help support responsible use of IVIg and disease monitoring.
Source: Journal of Neurology, Neurosurgery and Psychiatry - September 9, 2014 Category: Neurosurgery Authors: Pace, A. Tags: Abstracts Source Type: research

Effects of low frequency filtering on distal compound muscle action potential duration for diagnosis of CIDP: A Japanese-European multicenter prospective study
The diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) is based on a combination of specific clinical, electrodiagnostic, CSF, and other laboratory tests, and currently the diagnostic criteria proposed by the European Federation Neurological Societies/Peripheral Nerve Society (EFNS/PNS) are most frequently used for the diagnosis of CIDP (Hughes et al., 2006; Van den Bergh et al., 2010). Whereas multifocal demyelination is a diagnostic hallmark of CIDP, the distal nerve terminals, as well as the nerve roots, where the blood-nerve barrier is anatomically deficient, are preferentially affected, particularly...
Source: Clinical Neurophysiology - December 27, 2014 Category: Neuroscience Authors: Satsuki Mitsuma, Peter Van den Bergh, Yusuf A. Rajabally, Vinciane Van Parijs, Darren Martin-Lamb, Masahiro Sonoo, Akira Inaba, Toshio Shimizu, Sagiri Isose, Yasunori Sato, Tetsuo Komori, Sonoko Misawa, Satoshi Kuwabara, The Tokyo Metropolitan Neuromuscul Source Type: research

Effect Of FTY720 (Fingolimod) In A New Preclinical Rat Model For Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (P7.097)
CONCLUSIONS: Here we have shown the effects of FTY720 on chronic-EAN, an animal model of human CIDP. Our data demonstrate that FTY720 can suppress the chronicity of the disease and inhibit inflammation in PNS. These data confirm the interest of testing Fingolimod in human CIDP that is currently in progress in the FORCIDP study. Study Supported by: Novartis and AFM-Téléthon.Disclosure: Dr. Brun has nothing to disclose. Dr. Kremer has nothing to disclose. Dr. Trifilieff has nothing to disclose. Dr. De Seze has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brun, S., Kremer, L., Trifilieff, E., De Seze, J. Tags: Neuropathy: Clinical Trials, Diagnostic Testing, and Treatment Source Type: research

Impairment measures versus inflammatory‐RODS in GBS and CIDP: A responsiveness comparison
This study aimed to “define responder” through the concept of minimum clinically important differences using the individually obtained standard‐errors (MCID‐SE) and a heuristic “external criterion” responsiveness method in patients with Guillain‐Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). One hundred and fourteen newly diagnosed or relapsing patients (GBS: 55, CIDP: 59) were serially examined (1‐year follow‐up). The inflammatory‐Rasch‐built overall disability scale (I‐RODS), Rasch‐transformed MRC sum‐score (RT‐MRC), and Rasch‐transformed modifi...
Source: Journal of the Peripheral Nervous System - June 26, 2015 Category: Neurology Authors: Els K. Vanhoutte, Thomas H. P Draak, Kenneth C. Gorson, Sonja I. van Nes, Janneke G.J. Hoeijmakers, W. Ludo Van der Pol, Nicolette. C. Notermans, Eduardo Nobile‐Orazio, Jean‐Marc Léger, Peter Y.K. Van den Bergh, Giuseppe Lauria, Vera Bril, Hans Katzb Tags: RESEARCH REPORT Source Type: research

The (mis)diagnosis of CIDP: The high price of missing the mark
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated peripheral nervous system disorder classically presenting with progressive, symmetrical limb weakness including the proximal muscles, generalized areflexia, and large fiber sensory loss.1 Electrodiagnostic studies show unequivocal segmental demyelination in multiple motor nerves or nerve roots, and the CSF protein level is usually elevated. In addition to classical CIDP, there are many variant presentations, so-called atypical forms, such as pure motor, pure sensory, regional (restricted to the upper or lower limbs), multifocal (Lewis-Sumner syn...
Source: Neurology - August 10, 2015 Category: Neurology Authors: Gorson, K. C., Gooch, C. L. Tags: All Neuromuscular Disease, Peripheral neuropathy, Chronic inflammatory demyelinating polyneuropathy, Neuropathic pain, EMG EDITORIALS Source Type: research

Deregulated Fc{gamma} receptor expression in patients with CIDP
Conclusions: The FcR regulatory system is disturbed in patients with CIDP. Balancing activating vs inhibitory FcR expression might provide a clinical benefit for patients with CIDP.
Source: Neurology Neuroimmunology and Neuroinflammation - August 20, 2015 Category: Neurology Authors: Quast, I., Cueni, F., Nimmerjahn, F., Tackenberg, B., Lunemann, J. D. Tags: All Immunology, Autoimmune diseases, Chronic inflammatory demyelinating polyneuropathy Article Source Type: research

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins
Conclusions: Rituximab treatment is an option for patients with CIDP with IgG4 anti-CNTN1/NF155 antibodies who are resistant to conventional therapies. Classification of evidence: This study provides Class IV evidence that rituximab is effective for patients with treatment-resistant CIDP with IgG4 anti-CNTN1 or anti-NF155 antibodies.
Source: Neurology Neuroimmunology and Neuroinflammation - September 3, 2015 Category: Neurology Authors: Querol, L., Rojas-Garcia, R., Diaz-Manera, J., Barcena, J., Pardo, J., Ortega-Moreno, A., Sedano, M. J., Sero-Ballesteros, L., Carvajal, A., Ortiz, N., Gallardo, E., Illa, I. Tags: Class IV, Chronic inflammatory demyelinating polyneuropathy Article Source Type: research